The Bioavailability of CBD

CBD offers great health and healing benefits. Its high safety profile and non-addictive nature make it an attractive alternative to many conventional medicines.

But in order to be effective, CBD has to reach your endocannabinoid system. This means that it first has to be absorbed into the bloodstream, a concept known as bioavailability.

Once there, it has to remain in circulation long enough to reach the organs and tissues where it is needed.

Then, How much CBD is actually absorbed and used?

This depends on a process known as pharmacokinetics (how compounds are processed by the body).

In summary, pharmacokinetics refers to the sum of the mechanisms of absorption and elimination of your body, the characteristics of the body itself, the CBD and numerous external factors that can help or hinder the way in which you assimilate and use the CBD.

In addition, the route of entry, or method of administration, has much to do with the amount and speed with which the CBD enters the bloodstream.

CBD INGESTED (ORAL)

 can be incorporated into the coffee or the juice.

Oral formulations of CBD, such as the oils CBD, and other edibles, are among the most popular ways to consume CBD. CBD. However, the Oral CBD has the lowest bioavailability of all forms of supply.On average, the CBD ingested has a bioavailability of between 6 and 19%.One of the reasons is that CBD not easily absorbed when ingested and, as a result, most of it is excreted without exerting any effect. This is due to the fact that CBD is fat-soluble (unlike water-soluble), which makes it challenging for the body to absorb.

In addition, acids and digestive enzymes destroy a large percentage of the CBD before it has a chance to be absorbed. And the small amount that does make it through the intestinal wall is subject to metabolism by the liver before reaching the rest of the body.

The half-life of the Oral CBDi.e. the time it takes for half of the CBD to exit the bloodstream, it may be faster than other methods of administration. It has been reported half-lives from 10 to 17 hours for high doses of between 750 mg and 1500 mg.

Sublingual Drops (CBD Sublingual)

 

Drops of Sublingual CBD.

This method takes advantage of the capacity of the CBD to be absorbed directly through the mucous membranes of the mouth and nose, bypassing the digestive process and passing directly into the bloodstream.

The maximum levels The blood levels of this method, which consists of placing liquid drops of CBD under the tongue, have been measured in about two hours.

A simple way to improve the absorption of Sublingual CBD is to hold the drops under the tongue for 20-30 seconds before swallowing. This allows the mucous membranes more time to absorb the CBD before it enters the digestive tract.

CBD Topically (on the skin)

A scientific study suggests that the oil CBD can be beneficial for a number of different skin conditions. These may include:

Acne
Acne is the most common skin condition in humans. The CBD contains many compounds with oil-reducing, anti-inflammatory and antimicrobial properties that can help improve acne.

A study by 2014 explored the effects of CBD on human sebocytes. These are the cells that create sebum, which is a waxy, oily substance produced by the skin.

Although sebum helps protect our skin, excess sebum can also cause acne. The study suggests that CBD can prevent sebocytes from creating too much sebum.

A 2016 revision points to the possible antibacterial and antifungal properties of the cannabis plant. This could help prevent acne due to skin infections.

A 2019 study suggests that CBD may also be beneficial in treating the appearance of acne scars.

Learn more about CBD and acne here.

Dryness and itching

A 2019 study notes that CBD may be useful in treating some common symptoms of skin conditions, such as dryness and itching. The properties anti-inflammatory from CBD can be particularly helpful in reducing potential triggers of eczema, dermatitis and psoriasis.

As CBD oil can help soothe the skin and reduce the appearance of irritation, it may be useful for people with sensitive skin.

Learn more about CBD and psoriasis here.

Ageing and wrinkles
A 2017 study highlights the antioxidant properties of the CBD. Oxidative stressTrusted Source can contribute to the ageing process. Therefore, the properties antioxidants y anti-inflammatory CBD may help prevent the appearance of skin ageing.

Infection
As the cannabis plant may contain antibacterial properties and antifungal properties, it can be useful for treating skin infections.

Risks
According to the World Health Organisation (WHO), people generally tolerate CBD well. However, some common side effects of CBDwhich may be dose-dependent, may include

-mouthwashing
-somnolence
-fatigue
-diarrhoea
-changes in appetite and weight

SOURCES:

1. 1. 1. Taylor, L., Gidal, B., Blakey, G., Tayo, B., & Morrison, G. (2018). A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. CNS Drugs, 32(11), 1053-1067. doi:10.1007/s40263-018-0578-5
      2. Paudel, K. S., Hammell, D. C., Agu, R. U., Valiveti, S., & Stinchcomb, A. L. (2010). Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. Drug Dev Ind Pharm, 36(9), 1088-1097. doi:10.3109/03639041003657295
      3. Xu, C., Chang, T., Du, Y., Yu, C., Tan, X., & Li, X. (2019). Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model. Environ Toxicol Pharmacol, 70doi:10.1016/j.etap.2019.103202. doi:10.1016/j.etap.2019.103202
      4. Millar, S. A., Stone, N. L., Yates, A. S., & O'Sullivan, S. E. (2018). A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Front Pharmacol, 9, 1365. doi:10.3389/fphar.2018.01365
      5. Ujvary, I., & Hanus, L. (2016). Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy. Cannabis Cannabinoid Res, 1(1), 90-101. doi:10.1089/can.2015.0012
      6. Hlozek, T., Uttl, L., Kaderabek, L., Balikova, M., Lhotkova, E., Horsley, R. R., . . . . Palenicek, T. (2017). Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC. Eur Neuropsychopharmacol, 27(12), 1223-1237. doi:10.1016/j.euroneuro.2017.10.037
      7. Smith, D. M., O'Connor, R. J., Wei, B., Travers, M., Hyland, A., & Goniewicz, M. L. (2019). Nicotine and Toxicant Exposure among Concurrent Users ("Co-users") of Tobacco and Cannabis. Nicotine Tob Res. doi:10.1093/ntr/ntz122
      8. Hartman, R., Brown, T., Milavetz G., Spurgin A., Gorelick D., Gaffney G., Huestis, M. (2015). Controlled Cannabis Vaporizer Administration:Blood and Plasma Cannabinoids with and withoutAlcohol. Clinical Chemistry, 61:6, 850-869
      9. Stinchcomb, A. L., Valiveti, S., Hammell, D. C., & Ramsey, D. R. (2004). Human skin permeation of Delta8-tetrahydrocannabinol, cannabidiol and cannabinol. J Pharm Pharmacol, 56(3), 291-297. doi:10.1211/0022357022791
      10. Lodzki, M., Godin, B., Rakou, L., Mechoulam, R., Gallily, R., & Touitou, E. (2003). Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model. J Control Release, 93(3), 377-387. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/14644587
      11. Ohlsson, A., Lindgren, J. E., Andersson, S., Agurell, S., Gillespie, H., & Hollister, L. E. (1986). Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed Environ Mass Spectrom, 13(2), 77-83. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/2937482
      12. Taylor, L., Crockett, J., Tayo, B., & Morrison, G. (2019). A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment. J Clin Pharmacol, 59(8), 1110-1119. doi:10.1002/jcph.1412
      13. Birnbaum, A. K., Karanam, A., Marino, S. E., Barkley, C. M., Remmel, R. P., Roslawski, M., . . . . Leppik, I. E. (2019). Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. Epilepsy. doi:10.1111/epi.16093
      14. Cherniakov, I., Izgelov, D., Domb, A. J., & Hoffman, A. (2017). The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model. Eur J Pharm Sci, 109, 21-30. doi:10.1016/j.ejps.2017.07.00